Product
VIR-2218
Aliases
Elebsiran
9 clinical trials
7 indications
Indication
Hepatitis BIndication
ChronicIndication
Chronic Hepatitis BIndication
Liver ImpairmentIndication
CirrhosisIndication
Hepatitis DIndication
Renal ImpairmentClinical trial
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)Status: Active (not recruiting), Estimated PCD: 2024-01-23
Clinical trial
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2026-09-25
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2aStatus: Active (not recruiting), Estimated PCD: 2024-03-25
Clinical trial
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)Status: Recruiting, Estimated PCD: 2029-08-01
Clinical trial
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal ImpairmentStatus: Recruiting, Estimated PCD: 2025-05-15